Connect with us

Business

Wegovy Tablets (Oral Semaglutide), Explained:

Published

on

Wegovy Tablets (Oral Semaglutide), Explained:

The development of oral semaglutide for weight management marks an important shift in how GLP-1 medicines may be used in obesity care.

For several years, GLP-1 receptor agonists have been associated mainly with injectable treatments such as Wegovy and Mounjaro injectable pens. The arrival of Wegovy weight loss tablets changes that conversation by introducing a non-injectable option for eligible patients.

However, the significance of oral semaglutide is not simply that it avoids injections. It is also a formulation achievement. Semaglutide is a peptide-based medicine, and peptide medicines are naturally difficult to deliver by mouth because the digestive system is designed to break them down. Creating a tablet that can survive long enough in the stomach to be absorbed and produce a clinical effect is therefore a meaningful pharmaceutical development.

What is oral semaglutide?

Semaglutide is a GLP-1 receptor agonist. GLP-1, or glucagon-like peptide-1, is a hormone involved in appetite regulation, digestion and blood sugar control. GLP-1 receptor agonist medicines mimic some of the effects of this hormone, helping people feel fuller, reducing hunger and slowing the rate at which food leaves the stomach.

In weight management, semaglutide is used alongside dietary changes and increased physical activity. It is not a replacement for lifestyle change, but it can support people who are clinically eligible by reducing appetite and helping them sustain a lower-calorie intake.

Advertisement

The same active ingredient is used in different semaglutide products, but formulation and dose matter. Injectable semaglutide and oral semaglutide are not interchangeable unless a prescriber has advised a suitable switch. The oral tablet has its own dosing schedule, administration instructions and clinical considerations.

Why oral delivery is difficult

The digestive system presents several barriers to peptide medicines. Stomach acid and digestive enzymes can break down peptide molecules before they are absorbed. Even if the medicine survives long enough, large peptide molecules do not easily cross the gut lining into the bloodstream.

This is why GLP-1 receptor agonists have historically been delivered by injection. An injection bypasses the stomach and digestive enzymes, allowing the medicine to enter the body more reliably.

Oral semaglutide addresses this problem through the use of an absorption enhancer called SNAC, or sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. SNAC works locally in the stomach to help protect semaglutide from degradation and support absorption through the stomach lining.

Advertisement

This does not mean oral absorption becomes simple or complete. Only a small proportion of the swallowed dose is absorbed, which is why oral semaglutide uses higher milligram doses than injectable semaglutide like Wegovy pen. It also explains why administration instructions are so important.

Key considerations

One of the most important practical differences between oral and injectable semaglutide is how the tablet must be taken. Oral semaglutide needs to be taken on an empty stomach with a small amount of water, and patients must wait before eating, drinking anything other than water or taking other oral medicines.

This fasting window matters because food, drink and other medicines can reduce absorption. If the tablet is not taken correctly, less semaglutide may reach the bloodstream, which could affect the treatment’s clinical effect.

This means the tablet may be more appealing to people who prefer not to inject, but it still requires consistency and routine. A weekly injection may be easier for some patients; a daily tablet may be easier for others. The best option depends on medical suitability, lifestyle, treatment history and personal preference.

Advertisement

What the clinical data show

The OASIS 4 trial studied oral semaglutide 25mg once daily in adults with obesity or overweight with at least one weight-related complication. Participants also received lifestyle support, including reduced calorie intake and increased physical activity.

In the main analysis, participants taking oral semaglutide lost an average of 13.6% of their body weight after 64 weeks, compared with 2.2% in the placebo group. In an analysis assuming participants stayed on treatment and did not use additional anti-obesity interventions, average weight loss was 16.6% with oral semaglutide compared with 2.8% with placebo.

This distinction is important. The 13.6% result reflects the broader treatment-policy analysis, while the 16.6% result reflects a more idealised treatment-adherence scenario. Patient-facing discussions should avoid presenting the higher figure without explaining the context.

The study also showed that a greater proportion of people taking oral semaglutide achieved clinically meaningful weight loss thresholds, including at least 5%, 10%, 15% and 20% body weight reduction.

Advertisement

How oral semaglutide compares with injectable treatments

It is natural to compare the tablet with injectable Wegovy, but direct comparisons should be made carefully. Oral and injectable semaglutide have been studied in different trials, with different designs and populations. Similar-looking percentages do not necessarily prove equivalent effectiveness.

The oral formulation in Wegovy tablets may be especially relevant for people who are clinically eligible for GLP-1 treatment but are reluctant to use injections. Needle anxiety, storage concerns, travel plans, manual dexterity and preference for a tablet routine may all influence treatment choice.

At the same time, daily tablets are not automatically more convenient for everyone. Some patients may find a once-weekly injection simpler than a tablet that has to be taken under fasting conditions every morning.

Side effects and safety considerations

The side effect profile of oral semaglutide is broadly consistent with the GLP-1 medicine class. Gastrointestinal symptoms are the most common side effects, including nausea, vomiting, diarrhoea, constipation, indigestion and abdominal discomfort. These effects are often most noticeable during dose escalation.

Advertisement

More serious but less common risks may include gallbladder problems and pancreatitis. People should seek medical advice if they experience severe or persistent abdominal pain, especially if it is associated with vomiting or radiates to the back.

Oral semaglutide is a prescription-only medicine and is not suitable for everyone. Suitability depends on body mass index, weight-related health conditions, medical history, current medicines, contraindications and a clinical assessment by a qualified prescriber.

Patients should not buy weight loss medicines through social media, online marketplaces or unregulated sellers. Demand for GLP-1 medicines has increased rapidly, and counterfeit or inappropriate products can pose serious health risks.

What oral Wegovy could mean for pharmacies and patients

From a pharmacy industry perspective, oral Wegovy may change some of the practical considerations around GLP-1 treatment. Tablets may be simpler to store and distribute than refrigerated injectable pens, although they still need to be handled according to the authorised product information.

Advertisement

For patients, the tablet format may broaden choice. Some people may prefer a needle-free option, while others may prefer the simplicity of once-weekly dosing with an injection. The key is not that one format is universally better, but that different formulations may suit different patients.

Ana Carolina Goncalves, Superintendent Pharmacist at Pharmica Online Pharmacy, explains: “Oral semaglutide is significant because it gives eligible patients another way to access GLP-1 treatment, but it should not be seen as a casual or cosmetic option. Like injectable GLP-1 medicines, Wegovy tablets still require a thorough clinical assessment, careful dose escalation and ongoing attention to side effects, nutrition and long-term weight management habits.”

The future of oral GLP-1 treatment

The development of oral semaglutide points to a broader direction in obesity care: more treatment options, more patient choice and more innovation in how peptide-based medicines are delivered.

Oral semaglutide is best understood as a delivery innovation rather than a new mechanism of action. It uses the same GLP-1 pathway as established semaglutide treatments, but packages it in a way that may be more acceptable or practical for some patients.

Advertisement

The tablet format is an important step forward, but the fundamentals remain the same: GLP-1 medicines should be prescribed safely, used correctly and supported by sustainable changes to diet, physical activity and long-term health behaviours.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Holcim upgrades 2026 outlook after strong Q2 profit growth

Published

on


Holcim upgrades 2026 outlook after strong Q2 profit growth

Continue Reading

Business

Rain the key as WA looks to another record crop

Published

on

Rain the key as WA looks to another record crop

Western Australia could be on track for another record crop this year, though achieving that will depend heavily on better rainfall in August.

Continue Reading

Business

Optimism injection across North East companies as capital investment intentions revealed

Published

on

Business Live

Two well regarded pieces of research published this week point to positive signs among North East businesses

The Lloyds Business Barometer for April shows an increase in business confidence across the North East.

The latest Lloyds Business Barometer indicates that North East firms’ confidence is outstripping those in other regions.

North East firms reported increased confidence this month thanks to feelings about their own trading and the wider economy’s performance.

Research from Lloyds Business Barometer showed North East sentiment rose 21 points to 75%, compared with 54% in June. Companies experienced significantly higher confidence in their own trading outlook month-on-month, up eight points at 80% and optimism in the economy was up 34 points to 70%.

Improved outlook on the economy was said to have been driven by better economic data or news (52%) and improving inflation or cost measures (44%). Meanwhile confidence in their own trading outlook was driven by increased investment in capacity or technology (53%) along with improved economic conditions (43%).

A net balance of 50% of businesses in the region also said they expect to increase staff levels over the next 12 months – up four points on June. Looking ahead, respondents to the longstanding survey, said the top target areas for growth were technology, including AI and automation (55%); entering new markets (45%) and evolving their offering, including launching new products or services (37%).

Advertisement

Business confidence in the North East now sits above the 12-month average of 58%, with this month seeing its highest figure of 75%. Nationally, UK business confidence was up five points in July to 49% – a four-month high – driven by increased optimism about the economy thanks to falling global energy prices, the Bank of England holding interest rates and the announcement of an interim peace agreement in the Middle East at the time of the survey.

Martyn Kendrick, regional director for North East at Lloyds, said: “It is fantastic to see North East business confidence reach such a high, underlining the strength, ambition and resilience of firms across the region. Even more encouragingly, that optimism is being matched by clear plans for growth. Businesses are looking to invest in AI and automation, explore new markets and expand their teams over the year ahead.

“This record level of confidence reflects the real momentum building across the North East, and we will continue to support businesses as they invest, grow and seize the opportunities ahead.”

The Business Barometer findings come shortly after a separate piece of Lloyds research, which suggests more than half of North East firms plan to increase capital investment over the next year. That put the region above the 47% UK average, and on a similar level to London and the South East, with just 7% of firms expecting a decrease.

Advertisement

Amanda Murphy, CEO for Lloyds Business and Commercial Banking, said: “Despite heightened geopolitical uncertainty, it’s encouraging to see businesses planning to increase their capital investment. Firms need the right conditions to invest – whether that’s investing in AI, new technology, upgrading equipment or expanding capacity. It’s interesting that, while many businesses have already secured funding for investment, a significant proportion have yet to deploy it.

“Investment drives productivity, competitiveness, and long-term growth. Ensuring businesses have the confidence, funding and support to move forward will be critical. By helping firms unlock investment, we can support growth, boost productivity and strengthen the UK’s economic outlook.”

Continue Reading

Business

Positive Breakout: These 10 stocks cross above their 200 DMAs

Published

on

The Economic Times

In the Nifty500 pack, 10 stocks’ closing prices crossed above their 200 DMA (Daily Moving Averages) on July 30, 2026, according to stockedge.com’s technical scan data. The 200-day daily moving average (DMA) is used by traders as a key indicator for determining the overall trend in a particular stock. As long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend. Take a look:”​

Continue Reading

Business

Three things we learned about AI from Big Tech earnings

Published

on

Meta CEO Mark Zuckerberg stands in a crowd next to amazon Chairman Jeff Bezos and Google CEO Sundar Pichai.

AI tools may have not yet proven to be a consumer tech revolution on the scale of the internet or even electricity, external, as many tech executives have promised for years. But there is still huge demand from people for new technology.

Google said last week that 950 million people are using its Gemini chatbot at least once a month, three times the users it had a year ago.

Apple on Thursday said that new versions of its core products, the Mac computer, iPhone and iPad, have been selling better this year than the company planned for or expected.

So much so that it warned investors, external that sales of such products would slow down, because Apple is unable to get enough of the microchips that would be required to meet buyer demand.

Advertisement

The company is, however, anticipating a lot of excitement from Apple users for its impending update of Siri, its AI voice assistant within its products that is getting an overhaul with the help of Google’s Gemini chatbot.

Outgoing chief executive Tim Cook said Apple already has plans to charge users who wish to make heavier use of the new Siri, given feedback received from user testing so far.

“We’re off-the-charts excited about Siri AI”, Cook said. “We do believe there will be people who want to use it – a lot.”

Advertisement
Continue Reading

Business

Philadelphia-area CEO Brian Malloy dies ‘suddenly,’ weeks after taking helm

Published

on

Philadelphia-area CEO Brian Malloy dies 'suddenly,' weeks after taking helm

Carpenter Technology CEO Brian Malloy died suddenly just weeks after taking the helm of the specialty materials manufacturer, the company announced Monday.

Malloy, who became president and CEO July 1, died “suddenly and unexpectedly” Friday, July 24, according to a news release from the Philadelphia-based company

Advertisement

A cause of death was not disclosed.

“We are deeply saddened by Brian’s passing,” Carpenter Technology’s board of directors said in a statement.

PHILADELPHIA VOTERS APPROVE FIRST CITY-RUN RETIREMENT SAVINGS PROGRAM FOR WORKERS WITHOUT 401(K) PLANS

Carpenter Technology CEO Brian Malloy

Carpenter Technology CEO Brian Malloy died suddenly just weeks after taking the helm of the specialty materials manufacturer, the company announced Monday. (Facebook/Luiza Puculowski Malloy)

“Over the past decade, Brian made significant contributions to Carpenter Technology and was a respected leader with a strong commitment to performance, operational excellence, and the Company’s long-term success,” the board added. “We extend our deepest sympathies to Brian’s family and loved ones during this difficult time.”

Advertisement

The board appointed Executive Chairman Tony Thene to return as CEO, effective immediately. Thene, who led Carpenter Technology from 2015 through June 2026, will also remain chairman.

Malloy spent a decade at Carpenter Technology and had served as chief operating officer since 2023.

COMPANY BETS $200K ON AI TO MAKE TRADES WORKERS ‘BETTER, STRONGER, FASTER’

When the company announced Malloy’s appointment in February, Thene called him a “proven leader” with “deep operational experience” and a track record of delivering results across the company’s businesses.

Malloy said at the time that he was “honored” to be selected as the company’s next chief executive.

“I am honored to be named the next CEO of Carpenter Technology,” Malloy said in February. “Tony’s strategic vision has reshaped Carpenter Technology by building a culture of performance, strengthening our market position, and delivering meaningful value for all stakeholders.”

Ticker Security Last Change Change %
CRS CARPENTER TECHNOLOGY CORP. 503.71 -26.91 -5.07%

CRACKER BARREL CEO JULIE MASINO TO STEP DOWN

Advertisement
Carpenter Technology Logo

The board appointed Executive Chairman Tony Thene to return as CEO, effective immediately.  (Cheng Xin/Getty Images)

Before joining Carpenter Technology, Malloy held senior leadership roles at Ametek and Alcoa.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

A Carpenter Technology spokesperson told FOX Business the company would not comment further “out of respect for the privacy of the family.”

Advertisement
Continue Reading

Business

Capstone Copper Corp. (CS:CA) Q2 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

Operator

Good afternoon, and welcome to Capstone Copper’s Second Quarter 2026 Results Conference Call. [Operator Instructions]. This call is being recorded on Thursday, July 30, 2026. I would now like to turn the call over to Daniel Sampieri. Please go ahead.

Daniel Sampieri
Vice President of Investor Relations

Advertisement

Thank you, operator, and thank you, everyone, for joining us today to discuss our second quarter results. Please note that the news release and regulatory filings are available on our website and on SEDAR+. If you are logging into the webcast, we will advance the slides of today’s presentation, which are also available in the Investors section of our website.

I am joined today by our President and CEO, Cashel Meagher; our SVP and Chief Operating Officer, James Whittaker; our SVP and Chief Financial Officer, Ramanpreet Randhawa; and our SVP, Risk, ESG and our General Counsel, Wendy King. During the Q&A session at the end of the call, we will also be joined by our Head of Technical Services, Peter Amelunxen, who is available for questions.

Please note

Advertisement
Continue Reading

Business

Bajaj Finance shares rally 5% after Q1 results. What Nomura, Nuvama, other brokerages expect

Published

on

Bajaj Finance shares rally 5% after Q1 results. What Nomura, Nuvama, other brokerages expect
Shares of Bajaj Finance rallied 5% to Rs 1,108 on the BSE on Friday after the non banking financial company reported a 28% year-on-year growth in its standalone net profit at Rs 6,081 crore for the first quarter of FY27, with some brokerages raising target prices for the stock after the earnings print.

The company on Thursday reported a rise in net profit from Rs 4,765 crore recorded during the corresponding quarter of the previous financial year. Its net interest income (NII), meanwhile, increased 23% YoY to Rs 12,571 crore during the quarter under review.

Bajaj Finance’s AUM rose by Rs 36,969 crore during the first quarter. The company booked 16.13 million new loans in Q1, up 20% from 13.49 million in Q1 of FY26. Its customer franchise rose 17% to 124.43 million from 106.51 million a year ago, and the company added 5.1 million customers during the quarter.

Asset quality improved during the quarter. Gross NPA stood at 0.96% as of June 30, 2026, compared with 1.03% a year earlier. Net NPA stood at 0.39%, compared with 0.50% last year. Provisioning coverage ratio on stage 3 assets was 60%.

Advertisement

Nuvama on Bajaj Finance share price

Nuvama said Bajaj Finance posted a good set of numbers in Q1 with strong AUM growth of 24% YoY, stable NIMs unlike peers, steady improvement in asset quality and lower credit cost on guided lines, leading to profit beating estimate by 5%. Management guided for continued growth momentum while delivering profit growth ahead of AUM, led by cost discipline and risk management, it noted.

With growth re-accelerating and asset quality holding up well, leading to lower credit cost, Nuvama expects Bajaj Finance to deliver healthy RoA and RoE of around 4.1% and 20–21% respectively over FY27–29. However, due to its higher valuations, the brokerage has a ‘Hold’ rating on the stock.
Nuvama increased its target price for the shares of Bajaj Finance to Rs 1,175 apiece from Rs 1,050 apiece. The latest target price implies over 11.5% upside potential from the stock’s previous closing price of Rs 1,053.5 apiece on NSE.

Also read |
Bajaj Finance Q1 Results: Profit jumps 28% YoY to Rs 6,081 crore, NII surges 23%

Nomura

Nomura said that Bajaj Finance’s strong asset quality performance stole the show. The company’s operating profits were in line with the international brokerage’s estimates, but credit cost beat its and consensus estimates by 9%. “Despite the encouraging trends, management still highlighted global events related to uncertainty and monsoon fears in India. It plans to observe trends for another quarter before making any revision to guidance,” it noted.
Nomura continues to like Bajaj Finance among NBFCs and maintains its ‘Buy’ rating with a target price of Rs 1,140 apiece, implying an upside potential of more than 8% from the stock’s previous closing price.

Motilal Oswal

Motilal Oswal upgraded its rating on the shares of Bajaj Finance to ‘Buy’ and increased its target price to Rs 1,300 apiece, implying 23% upside potential. The domestic brokerage said the NBFC is firing on all cylinders, moving beyond the earnings normalization phase and entering a period of structurally higher earnings growth.

“The combination of broadbased loan growth, resilient margins, improving asset quality and declining credit costs is driving a meaningful acceleration in profitability. At the same time, new growth engines, including digital platforms, rapid gold loan expansion and new business launches, provide incremental optionality,” the domestic brokerage said as it raised its earnings estimates for Bajaj Finance.

Advertisement

Bajaj Finance share price

Bajaj Finance shares gained over 4% in a week and 5% in a month to close at Rs 1,053.50 apiece on Thursday. The stock has overall gained more than 20% in a year and nearly 45% in three years. In the longer term, it has delivered 70% returns over five years.

The stock is up 9% in 2026 so far and currently has a P/E ratio of nearly 34x. The company’s market capitalisation stands at Rs 6.59 lakh crore.

Also read | Bajaj Finance posts 28% growth in net profit amid healthy loan demand

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Advertisement
Continue Reading

Business

Why the U.S. Is Unlikely to Reduce China’s Dominance in Critical Minerals

Published

on

Why the U.S. Is Unlikely to Reduce China's Dominance in Critical Minerals

The U.S. hosted a summit on critical minerals to reduce China’s dominance in battery production, facing complex trade dynamics and investments linked to Chinese firms, especially in lithium-rich South America.


Key Points

  • The U.S. recently hosted a critical minerals summit to tackle China’s dominance in global battery production, focusing on sectors like smartphones and electric vehicles. This meeting involved countries such as Argentina, Australia, and the UK, signaling a shift in global trade dynamics.
  • China currently controls over 80% of global battery production, largely due to its low-cost manufacturing model, complicating U.S. efforts to reduce this reliance.
  • The United States is intensifying its actions to diminish Chinese involvement in South America, where more than 50% of the world’s lithium deposits are located.

The recent critical minerals summit hosted by the United States aimed to curtail China’s significant dominance in global battery production, particularly in the context of evolving trade dynamics and substantial public-private investments involving Chinese firms. This initiative is particularly pertinent given China’s overwhelming control over industries like smartphones, military weapon systems, lithium-ion batteries, and electric vehicles (EVs). The summit gathered representatives from nations rich in critical minerals, including Argentina, Australia, Bolivia, Canada, Chile, the Democratic Republic of Congo, India, the European Union, Japan, South Korea, and the United Kingdom. Canadian Prime Minister Mark Carney referred to this moment as a potential “rupture” in the established rules-based international order.

Upon examining the U.S. government’s tactics, which involve utilizing tariffs as a strategic tool, it becomes evident that the complexities of global trade coupled with the nuances of critical mineral supply chains present formidable challenges. American attempts to undermine China’s stronghold on this sector are complicated by existing intricate webs of investment agreements connected to Chinese enterprises. The International Energy Agency reports that China dominates over 80 percent of global battery production and an even more staggering 90 percent of grid-scale battery production, crucial for renewable energy storage.

The exponential growth in global battery sales—experienced sixfold since 2020—underscores China’s competitive advantage, driven by its low-cost manufacturing model. Grid-scale battery systems have similarly seen manufacturing expand by 20 times within the same period. In light of these statistics, the feasibility of the U.S. effectively reducing China’s role in critical mineral production and processing seems increasingly improbable.

In the past year, the U.S. has intensified its focus on diminishing China’s foothold in South America, a region notable for containing over 50 percent of the world’s known lithium deposits. This strategic pivot reflects a broader ambition to reshape global supply chains and mitigate dependency on Chinese production in critical sectors. However, the path forward remains fraught with challenges.

Advertisement

Read the original article : Why the U.S. is unlikely to curtail China’s critical minerals dominance

Continue Reading

Business

Airbus Logs Strong Earnings, Flags Confidence After Boost in Deliveries

Published

on

Airbus Logs Strong Earnings, Flags Confidence After Boost in Deliveries

Airbus AIR posted sharply higher earnings for the second quarter and said a recent uptick in plane deliveries made it confident that it would be able to meet its annual target.

The European aircraft maker said adjusted earnings before interest and taxes—its preferred measure of profitability—jumped 54% on year to 2.43 billion euros, equivalent to $2.77 billion. Meanwhile, net profit more than doubled to €1.66 billion.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Trending

Copyright © 2025